Sponsors Press Right to Appeal IRB Denials Directly to HHS

Executive Briefing Series
A A
Clinical trial sponsors should be allowed to appeal institutional review board (IRB) denials directly to the HHS, stipulate that only one IRB need oversee multi-site studies and standardize the content of trial data submissions, according to comments on a proposed rule.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $40.00